What is the DETECT-2 study?

DETECT-2 is a research study aiming to evaluate offering genetic testing to patients diagnosed with bowel, womb, and ovarian cancer at home.

This study is being led by Queen Mary University of London (Chief Investigator: Professor Ranjit Manchanda) and being delivered by a network of NHS hospital sites across the UK. The study is funded by GSK, the North East London Cancer Alliance, the North Central London Cancer Alliance and Barts Charity.